

# The Regulatory Hurdles and Challenges for Post Approval Changes of Legacy (Existing) Products

**PDA Australian Chapter**


**27 October 2015**



**BELSYME**  
CONSULTING

**Sonja Cuce**  
Principal Regulatory Consultant

# About Me



- 22 years experience in Pharmaceuticals and Medical Devices
- 15 years in Regulatory Affairs
- Manufacturing, planning, quality and management
- TGA Prescription Medicines IWG
- PDA AUS committee member 2004-2008
- Principal Regulatory Consultant Belsyme Pty Ltd

[sonja@cuce.com.au](mailto:sonja@cuce.com.au)

# Overview

- What are Legacy Products?
- Causes for Change – Quality
- Hurdles and Challenges
- Regulatory – Keys to Success
- Regulator Plan
- Opportunity and Benefits



# What are Legacy Products?

- Originally developed in the past (as early as 1930's).
- Dossier were developed when there was a lack of framework and regulation.
- Old Registered Products > 15 years
- Minimal Documentation regarding the Pharmaceutical Development or Validation



# What are Legacy Products?

- Legacy Products are refer to "grandfathered" products.
- Grandfathered products are products that were in the market before the commencement of the current legislation.
  - Australia: *Therapeutic Goods Act 1989* (i.e. in 1991)
  - New Zealand: *The Medicines Act 1981* and Medicines Regulations 1984

# Causes for Change- Quality

## Manufacturing Site Transfers

- Drug Product
- Drug Substance
- Testing sites

## Change to Manufacturing Process

- Equipment
- Use of new technology
- Method of manufacture
- Increase in batch size

## Formulation

- Reformulation
- Excipient
- Stability
- Container closure

## New Products

- New fill
- Pack sizes
- Extension of existing products into new markets

# Hurdles and Challenges

- Lack of Baseline Information
  - Regulatory dossier
  - Site documentation
- Project Scope
  - Poorly defined
  - Project creep
- Communication
  - Project management
  - Cross functional team

# Hurdles and Challenges

- Regulator engagement
  - Pre-submission Scientific/Strategy meeting
  - Audit
- Changes are based on Good Science not just cost or this is how we always did it.
- Non Quality consequential changes
- Hidden Markets
- Supply Strategy
- Cost



# Regulatory- Key to Success

- Involve RA during the scoping of your changes
- Project Plan
- Management commitment to the project
- Communicate changes of scope, regulation and delays
- Regulator engagement
- Realistic timeframes
- Good Data Package
- Document a Regulatory Plan/ Strategy and keep it updated.

# Regulatory Strategy

- Regulatory Strategy Plan documents the regulatory strategy for the implementation of a post approval change event or series of events.
- Initiated at any point of the post approval change cycle and is a living document intended to be updated as the project changes.
- Used to communicate to “in country” sales and marketing
- Not a change control but can be added as an addendum to a change control
- Dynamic – Electronic Document
- Version controlled - not a formal controlled document.

# Regulatory Strategy



# Opportunities and Benefits

- Harmonising process and products
- Regulatory compliance
- Regulator confidence
- Robust, reliable, product and processes
- Opportunities to extend products into new markets.
- Safer and consistent products
- Better Patient outcomes

# Contact Details



Sonja Cuce  
Principal Regulatory Consultant

Belsyme Pty Ltd



0417 128 304

[www.belsyme.com.au](http://www.belsyme.com.au)

[sonja@cuce.com.au](mailto:sonja@cuce.com.au)